Referrals

Updated 25 May 2023

The Drug Enforcement Administration (DEA) has announced a Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. The DEA is generally supportive of buprenorphine/naloxone treatment and has provided the extension to ensure patients get the medication they need.

Here are the significant aspects of the extension:

1. If you have not yet established tele-MOUD care with QuickMD, you must do so by November 11, 2023 for the DEA extension rules to apply to you and to be prescribed Suboxone by a QuickMD provider. 
2. Patents who have established tele-MOUD care with QuickMD prior to November 11, 2023 must download the form below, have it completed by a local physician in a face-to-face, in-person visit, and send it back to us before November 11, 2024.
3. The form can be completed by any practitioner including medical doctors (MDs), nurse practitioners (NPs), physician’s assistants (PAs), osteopathic physicians (DOs), and some dentists; however, they must have an active registration with the DEA.

What You Need To Do

Please print the form below, schedule a face-to-face visit with a local provider of your choice who is registered with the DEA, and return the form to us by:

Fax at (888) 777-1921, or

Email at referrals@quick.md

Form updated 5 Sep 2023

FAQs

The following answers are our current understanding of the DEA proposal. Answers subject to change.

Updated 25 May 2023